A Global Imatinib and Nilotinib Pregnancy Exposure Registry
Completed
- Conditions
- All Indications for Glivec/Gleevec and Tasigna
- Interventions
- First Posted Date
- 2011-02-03
- Last Posted Date
- 2015-04-15
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 4
- Registration Number
- NCT01289054
- Locations
- 🇺🇸
INC Research, LLC, Wilmington, North Carolina, United States
Efficacy of Nilotinib in Adult Patients With Gastrointestinal Stromal Tumors Resistant to Imatinib and Sunitinib.
- First Posted Date
- 2011-02-03
- Last Posted Date
- 2017-01-02
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 125
- Registration Number
- NCT01289028
- Locations
- 🇮🇹
Novartis Investigative Site, Torino, TO, Italy
BEZ235 Trial in Patients With HER2-(Human Epidermal Growth Factor Receptor 2 Negative) /HR+ (Hormonal Receptor Positive) Metastatic Breast Cancer
- First Posted Date
- 2011-02-02
- Last Posted Date
- 2012-06-07
- Lead Sponsor
- Novartis Pharmaceuticals
- Registration Number
- NCT01288092
Long Term Safety and Tolerability of QVA149 Versus Tiotropium in Japanese Patients With Chronic Obstructive Pulmonary Disease (COPD)
Phase 3
Completed
- Conditions
- Chronic Obstructive Pulmonary Disease (COPD)
- Interventions
- First Posted Date
- 2011-01-28
- Last Posted Date
- 2013-12-27
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 160
- Registration Number
- NCT01285492
- Locations
- 🇯🇵
Novartis Investigative Site, Wakayama, Japan
A Trial of Oral BEZ235 and BKM120 in Combination With Paclitaxel With or Without Trastuzumab
Phase 1
Completed
- Conditions
- Metastatic or Locally Advanced Solid Tumors
- Interventions
- First Posted Date
- 2011-01-28
- Last Posted Date
- 2020-12-09
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 110
- Registration Number
- NCT01285466
- Locations
- 🇨🇭
Novartis Investigative Site, St. Gallen, Switzerland
Safety and Tolerability of ASA404 Administered in Combination With Docetaxel in Japanese Patients With Solid Tumors
- First Posted Date
- 2011-01-28
- Last Posted Date
- 2020-12-09
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 9
- Registration Number
- NCT01285453
- Locations
- 🇯🇵
Novartis Investigative Site, Osaka, Japan
The Gilenya Pregnancy Registry
- First Posted Date
- 2011-01-28
- Last Posted Date
- 2025-01-22
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 312
- Registration Number
- NCT01285479
- Locations
- 🇬🇧
Novartis Investigative Site, Nottingham, United Kingdom
Evaluate the Efficacy and Safety of Pasireotide LAR (Long Acting Release) on the Treatment of Patients With Clinically Non-Functioning Pituitary Adenoma.
- First Posted Date
- 2011-01-26
- Last Posted Date
- 2019-04-26
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 20
- Registration Number
- NCT01283542
- Locations
- 🇧🇷
Novartis Investigative Site, Sao Paulo, SP, Brazil
A Study of BKM120 in Adult Japanese Patients With Advanced Solid Tumors
- First Posted Date
- 2011-01-26
- Last Posted Date
- 2020-12-08
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 15
- Registration Number
- NCT01283503
- Locations
- 🇯🇵
Novartis Investigative Site, Kashiwa, Chiba, Japan
Observational Registry Study of Renal Transplant Patients
Withdrawn
- Conditions
- Kidney Transplant
- First Posted Date
- 2011-01-26
- Last Posted Date
- 2017-02-27
- Lead Sponsor
- Novartis Pharmaceuticals
- Registration Number
- NCT01284257
- Locations
- 🇺🇸
Detroit investigational site, Detroit, Michigan, United States
🇺🇸Denver Investigational site, Denver, Colorado, United States
🇺🇸PHILADELPHIA investigational site, Philadelphia, Pennsylvania, United States
© Copyright 2025. All Rights Reserved by MedPath